Available SMI modes from Toshiba America Medical Systems
August 11, 2014 — Toshiba America Medical Systems is making it possible for clinicians to use ultrasound to see the smallest vessels in and around areas like tumors and lymph nodes, giving them a new way to diagnose disease faster and noninvasively.
Currently, physicians wanting to see low-velocity microvascular blood flow have to use contrast agents or more invasive modalities. Superb microvascular imaging (SMI) can dramatically improve the patient’s overall imaging experience by making exams safer and faster, getting them the diagnostic information needed.
SMI has received U.S. Food and Drug Administration (FDA) clearance for use on the Aplio 500 ultrasound system and was showcased at the Society of Vascular Ultrasound (SVU) annual conference in Lake Buena Vista, Fla.
“Toshiba ultrasound continues to push the envelope,” said Tomohiro Hasegawa, director, ultrasound business unit, Toshiba America Medical Systems. “With the development of SMI, clinicians can provide the right diagnosis on all patients earlier for improved care. Additionally, SMI expands the utility of ultrasound, which results in fewer ionizing procedures, improving patient safety.”
For more information: www.medical.toshiba.com
April 24, 2024 
